Biophytis (EPA:ALBPS) | WebDisclosure

REGULATED PRESS RELEASE

published on 04/08/2024 at 23:10, 1 year 11 months ago

Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)
Biophytis launches OBA Phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone), aiming to address muscle loss from obesity treatment and promising results in preclinical studies. Clinical study expected to start mid-2024 with results in 2025

Biophytis Clinical Study BIO101 OBA Phase 2 Obesity
REGULATED PRESS RELEASE

published on 04/08/2024 at 23:10, 1 year 11 months ago

Biophytis lance l'étude clinique de phase 2 OBA dans l'obésité avec BIO101 (20-hydroxyecdysone)
Biophytis lance l'étude clinique de phase 2 OBA pour traiter l'obésité avec BIO101 (20-hydroxyecdysone), visant à préserver la masse musculaire. Programme ayant des résultats prometteurs, début de l'étude prévu mi-2024

Biophytis Étude Clinique BIO101 Obésité OBA
BRIEF

published on 04/08/2024 at 23:09, 1 year 11 months ago

Biophytis annonce ses résultats financiers 2023 et fait le point sur ses activités

Biophytis Financement Développement Clinique Résultats Financiers 2023 BIO101
BRIEF

published on 04/08/2024 at 23:09, 1 year 11 months ago

Biophytis announces its 2023 financial results and provides an update on its activities

Biophytis Funding Clinical Development 2023 Financial Results BIO101
BRIEF

published on 04/08/2024 at 23:05, 1 year 11 months ago

Biophytis Announces Phase 2 Clinical Study in Obesity Treatment with BIO101

Biophytis Obesity Treatment BIO101 OBA Phase 2 Clinical Study GLP-1 Receptor Agonists
BRIEF

published on 04/08/2024 at 23:05, 1 year 11 months ago

Biophytis annonce une étude clinique de phase 2 sur le traitement de l'obésité avec BIO101

Biophytis BIO101 Étude Clinique De Phase 2 OBA Traitement De L'obésité Agonistes Des Récepteurs GLP-1
PRESS RELEASE

published on 04/08/2024 at 23:04, 1 year 11 months ago

Biophytis annonce ses résultats financiers 2023 et fait le point sur ses activités
Biophytis annonce ses résultats financiers 2023 et fait le point sur ses activités. Découvrez les principaux faits marquants et perspectives pour 2024 ainsi que les éléments financiers clés de l'année 2023

Biophytis Biotechnologie Développement Clinique Résultat Annuel Santé
PRESS RELEASE

published on 04/08/2024 at 23:04, 1 year 11 months ago

Biophytis announces its 2023 financial results and provides an update on its business activities
Biophytis announces 2023 financial results & updates business activities. Successfully developing clinical programmes & obtaining FDA approval for SARA-31 trial in sarcopenia

Biophytis FDA Approval 2023 Financial Results Clinical Programmes SARA-31 Trial
PRESS RELEASE

published on 04/08/2024 at 23:01, 1 year 11 months ago

Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)
Biophytis annonce ses résultats financiers 2023 et lance l'étude clinique de phase 2 OBA dans l'obésité avec BIO101 (20-hydroxyecdysone), confirmant son avancement dans le développement de traitements innovants

Biophytis Résultat Annuel Étude Clinique BIO101 Obésité
PRESS RELEASE

published on 04/08/2024 at 23:01, 1 year 11 months ago

Biophytis announces its 2023 financial results and provides an update on its business activities
Biophytis announces 2023 financial results & business update. Highlights: progress in clinical programmes, funding secured till 2025. Key focus on SARA, OBA, COVA, OBA, and MYODA programs

Financial Results Biophytis 2023 Funding Clinical Programmes

Published on 03/24/2026 at 08:01, 1 hour 11 minutes ago

Star Copper Confirms Copper Creek Mineralization
Published on 03/24/2026 at 07:00, 2 hours 12 minutes ago

Panther Minerals Earns In Under Rubidium Ridge Project Option
Published on 03/24/2026 at 07:00, 2 hours 12 minutes ago

Panther Completes Acquisition of Rubidium Ridge Project
Published on 03/24/2026 at 00:55, 8 hours 17 minutes ago

BTU Closes Oversubscribed Financing
Published on 03/23/2026 at 22:40, 10 hours 32 minutes ago

Troubadour Announces Withdrawal of Non-Brokered Private Placements

View all ACCESSWIRE

Published on 03/24/2026 at 09:05, 7 minutes ago

Nagarro announces preliminary numbers for FY 2025, guidance for FY 2026, and conclusion of independent investigation
Published on 03/24/2026 at 09:05, 7 minutes ago

MSI Highlights Cloud, AI, and Enterprise Server Platforms at CloudFest 2026
Published on 03/24/2026 at 09:02, 10 minutes ago

EQS-Adhoc: PAUL Tech AG secures EUR 40 million credit facility to support further growth
Published on 03/24/2026 at 09:00, 11 minutes ago

Original-Research: q.beyond AG (von NuWays AG): BUY
Published on 03/24/2026 at 09:00, 11 minutes ago

Original-Research: MAX Automation SE (von NuWays AG): BUY

View all EQS

Published on 03/24/2026 at 07:45, 1 hour 27 minutes ago

François Jackow’s appointment as a Board member will be submitted to the Annual General Meeting on May 7, 2026
Published on 03/24/2026 at 07:45, 1 hour 27 minutes ago

La nomination de François Jackow en tant que membre du Conseil d’administration sera soumise à l’Assemblée générale du 7 mai 2026
Published on 03/24/2026 at 07:30, 1 hour 42 minutes ago

Gimv secures new EUR 400 million revolving credit facility to support accelerated growth ambitions
Published on 03/24/2026 at 07:30, 1 hour 42 minutes ago

Gimv verzekert zich van een nieuwe Revolving Credit Facility van EUR 400 miljoen ter ondersteuning van de versnelde groeiambities
Published on 03/23/2026 at 19:08, 14 hours 4 minutes ago

Reporting on share buyback transactions carried out between March 16 and March 20, 2026

View all LES ECHOS COMFI WIRE

News